Collegium Announces Publication of Data on the In Vitro Assessment of IV Abuse of Xtampza ER in Journal of Opioid Management
Consistent with FDA’s guidance for developing abuse-deterrent formulations, the studies in the publication assess the ability to extract oxycodone for the purposes of IV abuse from Xtampza ER and active comparators. In addition, results from injectability and syringeability studies of Xtampza ER are included in the publication. Reformulated OxyContin® and immediate-release oxycodone were assessed as the active comparators.
The following link will take you to the full publication on the Journal of Opioid Management’s website: Link to Publication.
About
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza™ ER
Collegium’s lead product candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone, in development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Collegium developed Xtampza using its proprietary DETERx technology platform to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that we will obtain final approval for Xtampza ER or any of our other product candidates from the
Contact:Douglas Carlson Vice President, Corporate Development dcarlson@collegiumpharma.com